| dc.contributor.author |
Chatziioannou, Eftychia |
|
| dc.contributor.author |
Durak, Derya |
|
| dc.contributor.author |
Frey, Georg |
|
| dc.contributor.author |
Serna Higuita, Lina María |
|
| dc.contributor.author |
Rasch, Marie-Lena |
|
| dc.contributor.author |
Flatz, Lukas |
|
| dc.contributor.author |
Amaral, Teresa |
|
| dc.contributor.author |
Leiter-Stöppke, Ulrike |
|
| dc.date.accessioned |
2026-01-27T07:41:32Z |
|
| dc.date.available |
2026-01-27T07:41:32Z |
|
| dc.date.issued |
2025 |
|
| dc.identifier.issn |
1664-3224 |
|
| dc.identifier.uri |
http://hdl.handle.net/10900/174340 |
|
| dc.language.iso |
en |
de_DE |
| dc.publisher |
Lausanne : Frontiers Media Sa |
de_DE |
| dc.relation.uri |
http://dx.doi.org/10.3389/fimmu.2025.1524945 |
de_DE |
| dc.subject.ddc |
570 |
de_DE |
| dc.subject.ddc |
610 |
de_DE |
| dc.title |
Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis |
de_DE |
| dc.type |
Article |
de_DE |
| utue.quellen.id |
20250630000000_01935 |
|
| utue.personen.roh |
Lallas, Konstantinos |
|
| utue.personen.roh |
Chatziioannou, Eftychia |
|
| utue.personen.roh |
Durak, Derya |
|
| utue.personen.roh |
Frey, Georg |
|
| utue.personen.roh |
Serna-Higuita, Lina Maria |
|
| utue.personen.roh |
Rasch, Marie-Lena |
|
| utue.personen.roh |
Kyrgidis, Athanassios |
|
| utue.personen.roh |
Timotheadou, Eleni |
|
| utue.personen.roh |
Apalla, Zoe |
|
| utue.personen.roh |
Leiter, Ulrike |
|
| utue.personen.roh |
Flatz, Lukas |
|
| utue.personen.roh |
Lallas, Aimilios |
|
| utue.personen.roh |
Amaral, Teresa |
|
| dcterms.isPartOf.ZSTitelID |
Frontiers in Immunology |
de_DE |
| dcterms.isPartOf.ZS-Issue |
Article 1524945 |
de_DE |
| dcterms.isPartOf.ZS-Volume |
16 |
de_DE |
| utue.fakultaet |
04 Medizinische Fakultät |
de_DE |